Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered in a prime-boost regimen among Chinese infants: a randomized, double blind phase III clinical trial

This study aimed to evaluate the immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13). In total, 1200 infants were randomized into two groups with a 1:1 allocation and received a three-dose series of tested PCV13 or control PCV13 at ages 2, 4 and 6 months, respectively, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wenjuan, Liang, Qi, Zhu, Jiahong, Zhang, Junxia, Chen, Junsheng, Xie, Sulan, Hu, Yuemei, Li, Guifan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Pneumococcal – Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942447/
https://www.ncbi.nlm.nih.gov/pubmed/35192784
http://dx.doi.org/10.1080/21645515.2021.2019498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8942447/
https://www.ncbi.nlm.nih.gov/pubmed/35192784
http://dx.doi.org/10.1080/21645515.2021.2019498

Ejemplares similares